TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05987059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT Intervention
Description: Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT Intervention
Description: Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies.
Study: NCT06455917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of TIL Transfer and low dose IL-2
Description: The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment.~* TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0).~* Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses).
Study: NCT05558475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Coaching
Description: The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
Study: NCT04845321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-9945
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VNRX-9945
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Study: NCT05801328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ending of the wires on Erich arch bar in the occlusal direction
Description: The wires of the Erich arch bar will be placed on the occlusal direction
Study: NCT06118983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-TRANSFER-HF
Description: I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US.
Study: NCT06052163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo has no active properties and is taken orally.
Study: NCT06042777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture and TCM-based lifestyle management
Description: Non-pharmacological treatment based on traditional Chinese medicine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture and TCM-based lifestyle management
Description: Non-pharmacological treatment based on traditional Chinese medicine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture and TCM-based lifestyle management
Description: Non-pharmacological treatment based on traditional Chinese medicine.
Study: NCT05992870

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment.
Study: NCT04856930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Placebo
Study: NCT04550104

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Tablet [Lynparza]
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1390
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg iv infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 1500mg iv infusion
Study: NCT05111444

Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pyrotinib
Description: 320mg as continuous oral once daily on every 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
Study: NCT05233306

Intervention type: DEVICE
Intervention: MRI scanner (7 Tesla)
Description: MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
Study: NCT05111444

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen

Intervention type: DRUG
Group type: OTHER
Intervention: S-1
Description: Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
Study: NCT04704830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator
Study: NCT05259813

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWCAR029 (Relmacabtagene Autoleucel)
Description: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Study: NCT05065372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hcl 1000Mg Tab
Description: Agent used to modify insulin sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminohippurate Sodium 20 % Injection
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance

Intervention type: DRUG
Group type: OTHER
Intervention: Aminohippurate Sodium 20 % Injection
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aminohippurate Sodium 20 % Injection
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol 300 Mg/mL Injectable Solution
Description: Diagnostic aid/agent used to measure glomerular filtration rate

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol 300 Mg/mL Injectable Solution
Description: Diagnostic aid/agent used to measure glomerular filtration rate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol 300 Mg/mL Injectable Solution
Description: Diagnostic aid/agent used to measure glomerular filtration rate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
Study: NCT05555043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrisafe ip
Description: This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleWave System
Description: Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterlase iPlus
Description: Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
Study: NCT06064942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Narrative Therapy (MFNT)
Description: MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School services for families of children with ADHD
Description: Selected school social personnel will deliver services as usual for the control group.
Study: NCT05043571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
Study: NCT04974554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT
Description: FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Family Support
Description: Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
Study: NCT04776473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open treatment
Description: Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.

Intervention type: OTHER
Group type: OTHER
Intervention: Closed treatment
Description: Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
Study: NCT06385730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant anti-PD-1
Description: PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant anti-PD-1 with LDRT
Description: Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
Study: NCT06512012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga and exercise
Description: Technology-Assisted Yoga and Exercise Intervention during 6 months
Study: NCT04944654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
Study: NCT05857527

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Custom EMG triggered Soterix taVNS stimulation with CIMT therapy
Description: Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session.
Study: NCT04871269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04870411

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
Study: NCT05429788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose RLS103
Description: 3 mg CBD inhaled powder administered before public speaking challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose RLS103
Description: 6 mg CBD inhaled powder administered before public speaking challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo inhaled dry powder
Description: placebo inhaled powder administered before public speaking challenge
Study: NCT05402475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + Mindfulness
Description: Eight weeks of online CBT intervention combined with mindfulness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + Mindfulness
Description: Eight weeks of online CBT intervention combined with mindfulness
Study: NCT06082388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of atropine and isoprenaline
Description: Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of atropine and isoprenaline
Description: Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
Study: NCT05992103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty
Description: Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fundic Mucosal Ablation with ERBE HybridAPC
Description: Fundic mucosal ablation utilizing approved ERBE HybridAPC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo ESG
Description: Using only Apollo ESG as approved per label
Study: NCT05020171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group of strength training
Description: 2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group of physiotherapy not focus on strength training
Description: 2x a week during 5 weeks, active physical therapy treatment based on movement